Toxicity of quinolone antimicrobial agents

Journal of Toxicology and Environmental Health

Volumn 45, Issue 1, 1995, Pages 1-45

  Takayama, Satoshi ^a   Hirohashi, Masaaki ^a   Kato, Michiyuki ^a   Shimada, Hiroyasu ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AT 954; BAY O 9863; CINOXACIN; CIPROFLOXACIN; ENOXACIN; FLEROXACIN; LEVOFLOXACIN; LOMEFLOXACIN; NALIDIXIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIPEMIDIC ACID; PIROMIDIC ACID; QUINOLONE DERIVATIVE; S 7920; SPARFLOXACIN; TOSUFLOXACIN; TOSUFLOXACIN TOSILATE; UNCLASSIFIED DRUG;

ARTICULAR CARTILAGE; CARCINOGENICITY; CARDIOVASCULAR EFFECT; DRUG TOXICITY; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; NEUROTOXICITY; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; RAT; REPRODUCTIVE TOXICITY; REVIEW; TERATOGENICITY;

4-QUINOLONES; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE AND BONES; CARCINOGENS; CARDIOVASCULAR SYSTEM; CARTILAGE; CENTRAL NERVOUS SYSTEM; DERMATITIS, PHOTOTOXIC; DIGESTIVE SYSTEM; DNA DAMAGE; DRUG INTERACTIONS; HUMANS; MALE; MUTAGENS; REPRODUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TERATOGENS;

ANIMALIA;

EID: 0029028389     PISSN: 00984108     EISSN: None     Source Type: Journal    
DOI: 10.1080/15287399509531978     Document Type: Article

References (229)

1. Abe, H., Inokuchi, K., and Fujita, K. 1992. Effects of interactions between several new quinolone antimi-crobials and fenbufen on the responses of receptors for inhibitory amino acids in acutely isolated neurons from the rat hippocampus (CA1) 1. Ohyo Yakuri 44:679-683.
2. Abe, H., Inokuchi, K., and Fujita, K. 1993. Interaction of new quinolone antimicrobials and fenbufen in producing responses of GABA receptors in acutely isolated neurons from the rat hippocampus (CA1) (2). Ohyo Yakuri 46:29-32.
3. Adam, D. 1989. Use of quinolones in pediatric patients. Rev. Infect. Dis. 11 (suppl. 5):S1113-S1116.
4. Akahane, K., Sekiguchi, M., Une, T., and Osada, Y. 1989. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with y-aminobutyric acid receptor sites. Antimicrob. Agents Chemother. 33:1704-1708.
5. Akema, R., Okazaki, N., and Miyamoto, Y. 1978. On the mutagenicities of nalidixic acid and novobiocin. Bull. Kanagawa Public Health Lab. 8:47-48.
6. Alder, V. A., Clingle, S. J., and Constable, I. J. 1983. The retinal oxygen profile in cats. Invest. Ophthalmol. Vis. Sci. 24:30-36.
7. Andley, U. P. 1987. Photodamage to the eye. Photochem. Photobiol. 46:1057-1066.
8. Arcieri, G. M., Becker, N., Esposito, B., Griffith, E., Heyd, A., Neumann, C., and O’Brien, B. 1989. Safety of intravenous ciprofloxacin. A review. Am. I. Med. 87(suppl. 5A):92S-97S.
9. Ariga, M., Kurata, K., Miyazaki, Y., Kanou, M., and Nakagawa, H. 1982. Teratological study of AM-715 in rabbits. Kiso to Rinsyou 16:667-678.
10. Athar, M., Elmets, C. A., Bickers, D. R., and Mukhtar, H. 1989. A novel mechanism for the generation of superoxide anions in hematoporphyrin derivative-mediated cutaneous photosensitization: Activa-tion of the xanthine oxidase pathway. J. Clin. Invest. 83:1137-1143.
11. Baes, H. 1968. Photosensitivity caused by nalidixic acid. Dermatologica 136:61-64.
12. Bailey, R. R., Natale, R., and Linton, A. L. 1972. Nalidixic acid arthralgia. Can. Med. Assoc. I. 107:604-607.
13. Ball, P. 1986. Ciprofloxacin: An overview of adverse experiences. I. Antimicrob. Chemother. 18(suppl. D): 187-193.
14. Barret, J. E., Gootz, T. D., McGuirk, P. R., Farrell, C. A., and Sokolowski, S. A. 1989. Use of in vitro topoisomerase assays for studying quinolone antibacterial agents. Antimicrob. Agents Chemother. 33:1697-1703.
15. Basaran, A., Erol, K., Basaran, N., Gunes, H., Acikalin, E., and Timuralp, G. 1993. Effects of ciprofloxacin on chromosomes, and hepatic and renal functions in rats. Chemotherapy 39:182-188.
16. Bednarczyk, E. M., Green, J. A., Nelson, A. D., Leisure, G. A., Little, D., Adler, L. P., Berridge, M. S., Panacek, E. A., and Miraldi, F. D. 1991. Comparison of the effect of temafloxacin, ciprofloxacin, or placebo on cerebral blood flow, glucose, and oxygen metabolism in healthy subjects by means of positron emission tomography. Clin. Pharmacol. Ther. 50:165-171.
17. Bendele, A. M., Hulman, J. F., Harvey, A. K., Hrubey, P. S., and Chandrasekhar, S. 1990. Passive role of articular chondrocytes in quinolone-induced arthropathy in guinea pigs. Toxicol. Pathol. 18:304-312.
18. Berenblum, I., and Shubik, P. K. 1947. A new quantitative approach to the study of the stages of chemi-cal carcinogenesis in the mouse’s skin. Br. I. Cancer 1:386-391.
19. Birkett, D. A., Garretts, M., and Stevenson, C. J. 1969. Phototoxic bullous eruptions due to nalidixic acid. Br. J. Dermatol. 81:342-344.
20. Blomer, R., Bruch, K., Krauss, H., and Wacheck, W. 1986. Safety of ofloxacin-Adverse drug reactions reported during phase-ll studies in Europe and Japan. Infection 14(suppl. 4):S332-S334.
21. Bouissou, H., Caujolle, D., Caujolle, F., and Milhaud, G. 1978. Toxicologie experimentale.-Tissus car-tilagineux et acide nalidixique. C. R. Acad. Sci. Paris 286:D1743-1746.
22. Bowie, W., Willetts, V., and Jewesson, P. T. 1989. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob. Agents Chemother. 33:1778-1782.
23. Brauner, G. J. 1975. Bullous photoreaction to nalidixic acid. Am. J. Med. 58:576-580.
24. Bredberg, A., Brant, M., Riesbeck, K., Azou, Y., and Forsgren, A. 1989. 4-Quinolone antibiotics: Positive genotoxic screening tests despite an apparent lack of mutation induction. Mutât Res. 211:171-180.
25. Bruis, W. A., Slaper, H., Van Der Leu, J. C., and Berreus, L. 1984. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths. Pbotochem. Pbotobiol. 40:485-494.
26. Burkhardt, J. E., Hill, M. A., Carlton, W. W., and Kesterson, J. W. 1990. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet. Pathol. 27:162-170.
27. Burkhardt, J. E., Hill, M. A., Turek, J. J., and Carlton, W. W. 1992a. Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet. Pathol. 29:230-238.
28. Burkhardt, J. E., Hill, M. A., and Carlton, W. W. 1992b. Morphologic and biochemical changes in artic-ular cartilages of immature beagle dogs dosed with difloxacin. Toxicol. Pathol. 20:246-252.
29. Burkhardt, J. E., Hill, M. A., Lamar, C. H., Smith, G. N., Jr., and Carlton, W. W. 1993. Effects of difloxacin on the metabolism of glycosaminoglycans and collagen in organ cultures of articular cartilage. Fundam. Appl. Toxicol. 20:257-263.
30. Burry, J. N. 1974. Persistent phototoxicity due to nalidixic acid. Arch. Dermatol. 109:263.
31. Castora, F. J., Vissering, F. F., and Simpson, M. V. 1983. The effect of bacterial DNA gyrase inhibitors on DNA synthesis in mammalian mitochondria. Biochim. Biophys. Acta 740:417-127.
32. Chevalier, X., Albengres, E., Voisin, M.-C, Tillement, J.-P., and Larget-Piet, B. 1992. A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment. Drug Safety 7:310-314.
33. Christ, W., and Lehnert, T. 1990. Toxicity of the quinolones. In The new generation of quinolones, eds. C. Siporin, C. L. Heifetz, and J. M. Domagala, pp. 165-186. New York: Marcel Dekker.
34. Christ, W., Lehnert, T., and Ulbrich, B. 1988. Specific toxicologic aspects of the quinolones. Rev. Infect. Dis. 10:S141-S146.
35. Chysky, V., Kapila, K., Hullmann, R., Arcieri, G., Schacht, P., and Echols, R. 1991. Quinolones in clinical use. Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 19:289-296.
36. Ciaravino, V., Suto, M. J., and Rheiss, J. C. 1993. High capacity in vitro micronucleus assay for assess-ment of chromosome damage: Results with quinolone/naphthyridone antibacterials. Mutât. Res. 298:227-236.
37. Clerch, B., Barbé, J., and Llagostera, M. 1992. The role of the excision and error-prone repair systems in mutagenesis by fluorinated quinolones in Salmonella typhimurium. Mutât. Res. 281:207-213.
38. Cook, T. M., Goss, W. A., and Deitz, W. H. 1966. Mechanism of action of nalidixic acid on Escherichia coli. I. Bacteriol. 91:780-783.
39. Corraddo, M., Struble, W. E., Peter, C, Hoagland, V., and Sabbaj, J. 1987. Norfloxacin: Review of safety studies. Am. I. Med. 82(suppl. 6B):22-26.
40. Deaney, N. B., Vogel, R., Vandenburg, M. J., and Currie, W. J. C. 1984. Norfloxacin in acute urinary tract infections. Practitioner 1228:111-117.
41. Dillehay, L. E., Kram, D., and Williams, J. R. 1989. DNA topoisomerases and models of sister-chromatid exchange. Mutât. Res. 215:15-23.
42. Dodo, M., Nakatsuji, K., Miura, Y., Hori, M., Furukawa, K., Oka, M., and Ito, T. 1991. General phar-macology of sparfloxacin, a new quinolone antibacterial agent. (1) Effects on the central nervous system. Ohyo Yakuri 41:147-155.
43. Doteuchi, M., Oka, M., and Ohuchi, T. 1980. Pharmacologic actions of cinoxacin on the respiratory and cardiovascular systems and smooth muscles. Chemotherapy 28(S-4):550-559.
44. Doull, J., and Bruce, M. 1986. Origin and scope of toxicology. In Casarett and Doull’s Toxicology, 3rd ed., eds. C. Klaassen, M. Amdur, and J. Doull, pp. 3-10. New York: Macmillan.
45. Ebling, F.J. 1977. Hormonal control and mammalian skin gland. In Chemical signal in vertebrates, eds. D. Muller-Schwarze and M. M. Mozell, pp. 17-33. New York: Plenum Press.
46. Ferguson, J., Philips, G., and McEwen, J. 1988. Loss of antibiotic activity caused by photodegradation: In vitro studies. Br. J. Dermatol. 119:550-551.
47. Fernandez, E. B., and Cardenas, A. M. G. 1990. The mechanism of photohemolysis by photoproducts of nalidixic acid. J. Photochem. Photobiol. B4:329-333.
48. Fernandez, E. B., Cardenas, A. M. G., and Martinez, G. S. 1987. Phototoxicity from nalidixic acid: Oxygen-dependent photohemolysis. Farmaco Ed. Sci. 42:681-690.
49. Filippova, L. M., and Yefremova, G. I. 1974. Mutagenic and modificational activity of nevigramon. Cenetika 10:165-166.
50. Food and Drug Administration. 1993. FDA committee urges stronger warnings on Searle’s Maxaquin. SCRIP 1810:11-32.
51. Forster, C., Baumann-Wilschke, I., and Stahlmann, R. 1993. Binding capacity of quinolones to cartilage components. Drugs 45 suppl. 31:283-285.
52. Fox, R. B. 1984. Prevention of granulocyte-mediated oxidant lung injury in rats by hydroxyl radical scavenger, dimethylthiourea. J. Clin. Invest. 74:1456-1464.
53. Fujii, T., Furukawa, H., Miyazaki, H., and Hashimoto, M. 1984. Disposition and metabolism of [UC]AT- 2266, II. Repeated administration. Chemotherapy 32(S-3): 136-141.
54. Fujii, K., and 67 others. 1990. Evaluation of norfloxacin in the pediatric field. Ipn. I. Antibiot. 18:181-214.
55. Funabashi, H., Mukumoto, K., Shigematsu, K., Nishimura, K., and Ohnishi, K. 1991a. Reproductive and developmental toxicity studies of sparfloxacin (2). Teratogenicity study in rats. Yakuri to Chiryou 19:1257-1274.
56. Funabashi, H., Mukumoto, K., Imura, Y., Nishimura, K., and Ohnishi, K. 1991b. Reproductive and developmental toxicity studies of sparfloxacin (3). Perinatal and postnatal study in rats. Yakuri to Chiryou 19:1275-1289.
57. Furuhama, K., Akahane, K., Tawara, K., and Takayama, S. 1992. Interaction of the new quinolone antibacterial agent levofloxacin with fenbufen in mice. Arzneim.-ForschJDrug Res. 42:406-408.
58. Geddes, A. M. 1993. Safety of fleroxacin in clinical trials. Am.l. Med. 94:201S-203S.
59. German, A., Panouse-Perrin, J., and Ardouin, A. C. 1969. Mutagenic action of nalidixic acid on staphy-lococcal phage. C. R. Acad. Sci. 268:1827-1829.
60. Girotti, A. W. 1983. Mechanism of photosensitization. Photochem. Photobiol. 38:745-751.
61. Gocke, E. 1991. Mechanism of quinolone mutagenicity in bacteria. Mutat. Res. 248:135-143.
62. Goldsworthy, T. L., Hanigan, M., and Pitot, H. 1986. Models of hepatocarcinogenesis in the rats- Contrast and comparisons. CRC Crit. Rev. Toxicol. 17:61-89.
63. Gough, A., Barsoum, N. J., Mitchell, L., McGuire, E. J., and De La Iglesia, F. A. 1979. Juvenile canine drug-induced arthropathy: Clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol. Appl. Pharmacol. 51:177-187.
64. Halkin, H. 1988. Adverse effects of the fluoroquinolones. Rev. Infect. Dis. 10(suppl.):S258-S261.
65. Haward, B. M., Pinney, R. J., and Smith, J. T. 1993. Function of SOS process in repair of DNA damage induced by modern 4-quinolones. J. Pharm. Pharmacol. 45:658-662.
66. Hayem, G., Petit, P. X., Levacher, M., Gaudin, C., Kahn, M.-F., and Pocidalo, J.-J. 1994. Cytofluoro- metric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob. Agents Chemother. 38:243-247.
67. Hildebrand, H., Kempka, G., Schluter, G., and Schmidt, M. 1993. Chondrotoxicity of quinolones in vivo and in vitro. Arch. Toxicol. 67:411-415.
68. Hirai, S., Hiraiwa, T., Arai, H., Ono, S., Tanaka, K., Hashiba, K., Nakada, Y., Goden, K., Tanada, K., Maekawa, M., Furuhata, K., Makino, S., and Kitamura, K. 1989a. General pharmacology of T- 3262, a new pyridonecarboxylic acid. Ipn.J. Antibiot. 42:831-853.
69. Hirai, S., Tanaka, K., Makino, S., and Narita, H. 1989b. Adverse drug interactions between pyridonecar-boxylic acids and nonsteroidal antiinflammatory drugs: Convulsion after oral or intracerebral administration in mice. Yakugaku Zasshi 109:119-126.
70. Holden, H. E., Barett, J. F., Huntington, C. M., Muehlbauer, P. A., and Wahrenburg, M. G. 1989. Genetic profile of a nalidixic acid analog: A model for the mechanism of sister chromatid exchange induction. Environ. Mol. Mutagen. 13:238-252.
71. Hori, S., Shimada, J., Shiba, K., Yoshida, M., Saito, A., and Sakai, O. 1991. A study on convulsive effects of sparfloxacin with or without non-steroidal anti-inflammatory drugs. Chemotherapy 39:161-166.
72. Hoshino, K., Sato, K., Akahane, K., Yoshida, A., Hayakawa, I., Sato, M., Une, T., and Osada, Y. 1991. Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob. Agents Chemother. 35:309-312.
73. Howard, L. C., VanSickle, D. C., Deshmukh, K., Criffing, W. J., and Owen, N. V. 1979. Cinoxacin- induced arthropathy in juvenile beagle dogs. Toxicol. Appl. Pharmacol. 48:A145.
74. Hoy, C. A., Salazar, E. P., and Thompson, L. H. 1984. Rapid detection of DNA-damaging agents using repair-deficient CHO cells. Mutat. Res. 130:321-332.
75. Hussy, P., Maas, G., Tummler, B., Grosse, F., and Schamburg, U. 1986. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase complex, topoisomerase I and II, and growth of mam-malian lymphoblast. Antimicrob. Agents Chemother. 29:1073-1078.
76. Imai, S., Nomoto, Y., Kasai, M., Ohtake, S., Tanase, H., and Yoshida, Y. 1990a. Subacute oral toxicity study of fleroxacin in rats. Chemotherapy 38(S-2):145-174.
77. Imai, S., Nomoto, Y., Kasai, M., Ohtake, S., Toriyabe, T., and Tanase, H. 1990b. Subacute oral toxicity study of fleroxacin in dogs. Chemotherapy 38(S-2): 175-202.
78. Ingham, B., Brentnall, D. W., Dale, E. A., and McFadzean, J. A. 1977. Arthropathy induced by antibacterial fused N-alkyl-4 pyridone-3-carboxylic acid. Toxicol. Lett. 1:21-26.
79. Irikura, T., and Hosomi, J. 1981. The mutagenicity of AM-715 in vitro. Chemotherapy 29(S-4):938-945.
80. Irikura, T., Sugimoto, T., Ajima, H., and Tsuchiya, T. 1981a. Toxicological study of AM-715. (4) Chronic toxicity study in rats. Chemotherapy 29(S-4):829-848.
81. Irikura, T., Sugimoto, T., Imai, S., Ikeda, T., Tanase, H., and Kanda, K. 1981b. Toxicological study of AM-715. (5) Chronic toxicity study in dogs. Chemotherapy 29(S-4):849-885.
82. Irikura, T., Suzuki, H., and Sugimoto, T. 1981c. Reproduction studies of AM-715. (1) Fertility study. Chemotherapy 29(S-4):886-894.
83. Irikura, T., Suzuki, H., and Sugimoto, T. 1981 d. Reproduction studies of AM-715 in mice. (2) Teratological study. Chemotherapy 29(S-4):895-914.
84. Irikura, T., Imaida, O., Suzuki, H., and Abe, Y. 1981e. Teratological study of AM-715 in rats. Kiso to Rinsyo 15:67-79.
85. Irikura, T., Suzuki, H., and Sugimoto, T. 1981 f. Reproduction studies of AM-715 in mice. (3) Perinatal and postnatal study. Chemotherapy 29(S-4):9T5-931.
86. Irikura, T., Hirayama, T., Ohkubo, H., Itoh, Y., and Nishino, K. 1981 g. Influence of AM-715 on the retina of cats. Chemotherapy 29(S-4):946-952.
87. Irikura, T., Suzuki, H., and Sugimoto, T. 1981 h. Mutagenicity studies of AM-715 in animals. Chemotherapy 29(S-4):932-937.
88. Isozaki, T., and Matsuno, Y. 1971. Pharmacological studies on piromidic acid. Chemotherapy 19:394403.
89. Ito, A., Hirai, K., Inoue, M., and Mitsuhashi, S. 1981. In vitro and in vivo antibacterial of AM-715. Chemotherapy 29(S-4): 1-11.
90. Ito, K., Murakami, K., and Tamura, K. 1993. a,-Adrenoceptor-blocking activity of ofloxacin and ciprofloxacin in isolated vascular smooth muscles. Arch. Int. Pharmacodyn. Ther. 325:86-95.
91. Ito, N., Tsuda, H., Tatematsu, M., Inoue, T., Tagawa, Y., Aoki, T., Uwagawa, S., Kagawa, M., Ogiso, T., Masui, T., Imaida, K., Fukushima, S., and Asamoto, M. 1988. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione 5-transferase placental form positive foci in rats-An approach for new medium-term bioassay system. Carcinogenesis 9:387-394.
92. Kada, T., Tutikawa, K., and Sadaie, Y. 1972. In vitro and host-mediated “rec-assay” procedure for screening chemical mutagens; and phloxine, a mutagenic red dye detected. Mutat. Res. 16:165-174.
93. Kajimura, T., Tojo, H., Kudo, G., Yamada, M., Donon, S., Nomura, M., and Takayama, S. 1992. Effects of the new quinolone antibacterial agent levofloxacin on multiple organ carcinogenesis initiated with wide-spectrum carcinogens in rats. Arzneim.-ForschJDrug Res. 42:390-395.
94. Kato, M., and Onodera, T. 1988a. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fundam. Appl. Toxicol. 11:110-119.
95. Kato, M., and Onodera, T. 1988b. Effect of ofloxacin on the uptake of [3H]thymidine by articular carti-lage cells in the rat. Toxicol. Lett. 44:131-142.
96. Kato, M., and Onodera, T. 1988c. Morphological investigation of osteochondrosis induced by ofloxacin in rats. Fundam. Appl. Toxicol. 11:120-131.
97. Kessel, D. 1984. Hematoporphyrin and HPD: Photophysics, photochemistry and phototherapy. Photochem. Photobiol. 39:851-859.
98. Kojima, H., Hirohashi, M., Sakurai, T., Kasai, Y., and Akashi, A. 1984. General pharmacology of DL-8280. Chemotherapy 32(S-1):1148-1161.
99. Konicek, J., and Konickova-Radochova, M. 1982. Nalidixic acid mutagenicity in Mycobacterium pheli. Stud. Pneumol. Phtiseol. Cech. 42:234-237.
100. Kowalczyk, J. 1980. Sister-chromatid exchanges in children treated with nalidixic acid. Mutat. Res. 77:371-375.
101. Krajcovic, J., Ebringer, L., and Polonyi, J. 1989. Quinolones and coumarins eliminate chloroplasts from Euglena gracilis. Antimicrob. Agents Chemother. 33:1883-1889.
102. Kurosawa, T., and Ikezawa, Z. 1992. Two cases of drug eruption induced by enoxacin-A study of cross-reactivity between pyridonecarboxylic acids. Rinsho-Hifu 46:929-933.
103. LeBel, M. 1991. Fluoroquinolones in the treatment of cystic fibrosis: A critical appraisal. Eur. J. Clin. Microbiol. Infect. Dis. 10:316-324.
104. Lefever, P. A., and Ashby, B. J. 1985. Investigations into the reported ability of cimetidine to initiate UDS in rat hepatocyte primary culture. Environ. Mutagen. 7:833-837.
105. Leigh, D. A., Tait, S., and Walsh, B. 1991. Antibacterial activity of lomefloxacin./. Antimicrob. Chemother. 27:589-598.
106. Lesher, G., Froelich, E., Gruet, M., Bailey, J., and Brundage, R. 1962. 1, 8-Naphthyridine derivatives: A new class of chemotherapeutic agents. J. Med. Pharm. Chem. 5:1063-1068.
107. Levin, D. E., Marnett, L. J., and Ames, B. N. 1984. Spontaneous and mutagen-induced deletions: Mechanistic studies in Salmonella tester strain TA102. Proc. Natl. Acad. Sci. USA 81:4457-4461.
108. Lucas, P. D., Donohoe, S. M., and Thody, A. J. 1982. The role of estrogen and progesterone in the con-trol of preputial gland sex attractant odors in the female rat. Physiol. Behav. 8:601-607.
109. Machida, M., Kusajima, H., Aijima, H., Maeda, A., Ishida, R., and Uchida, H. 1990. Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. Toxicol. Appl. Pharmacol. 105:403-412.
110. Mamber, S. W., Kolek, B., Brookshire, K. W., Bonner, D. P., and Fung-Tomc, J. 1993. Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays. Antimicrob. Agents Chemother. 37:213-217.
111. Marutani, K., Matsumoto, M., Otabe, Y., Nagamura, M., Tanaka, K., Miyoshi, A., Hasegawa, T., Nagano, H., Matsubara, S., Kamide, R., Yokota, T., Matsumoto, F., and Ueda, Y. 1993. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at 8 position in mice irradiated with long-wavelength UV light. Antimicrob. Agents Chemother. 37:2217-2223.
112. Matsuno, Y., Sohji, Y., and Shimizu, M. 1975. Pharmacological studies on pipemidic acid. Chemo-therapy 23:2671-2684.
113. Matsuno, Y., Taira, N., and Kadokawa, T. 1984. General pharmacological properties of AT-2266. Chemotherapy 32(S-3):164-184.
114. Maura, A., and Pino, A. 1988. Evaluation of the DNA-damaging and mutagenic activity of oxalinic acid and pipemidic acids by the granuloma pouch assay. Mutagenesis 3:397-401.
115. Maura, A., and Pino, A. 1991. Induction of sperm abnormalities in mice by norfloxacin. Mutat. Res. 264:197-200.
116. McCoy, E. C., Petrullo, L. A., and Rosenkranz, H. S. 1980. Non-mutagenic genotoxigens: Novobiocin and nalidixic acid, 2 inhibitors of DNA gyrase. Mutat. Res. 79:33-43.
117. McQueen, C. A., and Williams, G. M. 1987. Effects of quinolone antibiotics in test for genotoxicity. Am. I. Med. 82(suppl. 4A):94-96.
118. McQueen, C. A., Way, B. M., Queener, S. M., Schluter, G., and Williams, G. A. 1991. Study of potential in vitro and in vivo genotoxicity in hepatocytes of quinolone antibiotics. Toxicol. Appl. Pharmacol. 111:255-262.
119. Ministry of Health and Welfare, Pharmaceutical Affairs Bureau, Tokyo. 1986. Drug Side Effect Information No. 81 (Public notification).
120. Mitelman, F., Kolnig, A.-M., Strombeck, B., Norrby, R., Kromann-Andersen, B., Sommer, P., and Wadstein, J. 1988. No cytogenetic effects of quinolone treatment in humans. Antimicrob. Agents Chemother. 32:936-937.
121. Monk, J. P., and Campoli-Richards, D. M. 1987. Ofloxacin. A review of its antibacterial activity, phar-macokinetic properties and therapeutic use. Drugs 33:346-391.
122. Moore, D. E., Hemmens, V. J., and Yip, H. 1984. Photosensitization by drugs: Nalidixic and oxolinic acids. Photochem. Photobiol. 39:57-61.
123. Moore, M. 1993. 2-Year dietary oncogenicity in rats with DR-3355. Performing Laboratory: Hazleton Washington, Inc. (unpublished).
124. Morikawa, K., Hashimoto, S., Iwanaga, Y., Yamauchi, T., and Yamazaki, M. 1988a. General pharma-cology of NY-198 I. Effects on the central nervous system, respiration and cardiovascular system. Chemotherapy 36(S-2):265-283.
125. Morikawa, K., Hashimoto, S., Iwanaga, Y., Makino, E., and Yamazaki, M. 1988b. General pharmacology of NY-198 II. Effects on the autonomic nervous system, peripheral nervous system and others. Chemotherapy 36(S-2):284-299.
126. Morliere, P. 1986. Drug-induced photosensitivity: Phototoxic and photoallergic reactions-A few molecular aspects. Biochimie 68:849-855.
127. Morrissey, E. 1989. Toxicology and carcinogenesis studies of nalidixic acid in F344/N rats and B6C3F, mice. Bethesda, Md.: U.S. Department of Health and Human Services, Public Service, NIH, Report No. 368.
128. Mukherjee, A., Sen, S., and Agarwal, K. 1993. Ciprofloxacin: Mammalian DNA topoisomerase type II poison in vivo. Mutat. Res. 301:87-92.
129. Murayama, S., Hirai, K., Ito, A., Abe, Y., and Irikura, T. 1981. Studies on absorption, distribution and excretion of AM-715 in animals by bioassay method. Chemotherapy 29(S-4):98-104.
130. Murayama, S., Hara, Y., Ally, A., Suzuki, T., and Tamagawa, M. 1992. Central stimulating effect of the combination of the new quinolone group of antimicrobials and nonsteroidal anti-inflammatory drugs in mice. Folia Pharmacol. Jpn. 99:13-18.
131. Nagatsu, Y., Endo, K., and Irikura, T. 1981. Studies on the fate of, 4C-labelled AM- 715. Chemotherapy 29(S-4): 105-118.
132. Nakada, H., Nakamura, S., Komae, N., Sanzen, T., Nojima, Y., Akasaka, M., Nishio, Y., and Yoneda, T. 1988. Reproduction studies of T-3263 in rats. Chemotherapy 36:294-319.
133. Nakatsuji, K., Kii, Y., Miura, Y., and Ito, T. 1991. General pharmacology of sparfloxacin, a new quinolone antibacterial agent. (2) Effects on respiratory, cardiovascular and autonomic nervous system functions. Ohyo Yakuri 41:157-164.
134. Nakamura, S., Kurobe, N., Kashimoto, S., Ohue, T., Takase, Y., and Shimizu, M. 1984. Absorption, dis-tribution, excretion and metabolism of AT-2266 in experimental animals. Chemotherapy 32(S-3): 86-94.
135. Nakazima, M., and Uematsu, T. 1991. Quinolone antimicrobial agents from the view point of clinical pharmacodynamics. In Quinolone antimicrobial agents, eds. Y. Ueda, K. Shimizu, M. Konno, and H. Matsumoto, pp. 99-106. Tokyo: Life Science.
136. Naora, K., Katagiri, Y., Ichikawa, N., Hayashibara, M., and Iwamoto, K. 1991. Enhanced entry of ciprofloxacin into the rat central nervous system induced by fenbufen. J. Pharmacol. Exp. Ther. 258:1033-1037.
137. Nickerson, P. A., Freman, J. J., and Brownie, A. C. 1976. Effect of testosterone propionate on the ultra-structure of preputial gland in the rat. Acta Anat. 94:481-489.
138. Nishimura, K., Mukumoto, K., Nanto, T., Terada, Y., Yasuba, J., Sasaki, H., Fukagawa, S., Shigematsu, K., and Tatsumi, H. 1976. Reproduction studies of pipemidic acid in rats. III. Perinatal and postnatal study, lyakuhin Kenkyu 7(3):330-339.
139. Nishimura, K., Mukumoto, K., Terada, Y., Takenaka, H., and Yoshida, K. 1984a. Reproduction studies of AT-2266. (5) Teratogenicity study in dogs. Chemotherapy 32(S-3):327-333.
140. Nishimura, K., Mukumoto, K., Tsuruta, K., Imura, Y., Yoshioka, M., and Yoshida, K. 1984b. Repro-duction studies of AT-2266. (4) Perinatal and postnatal study in rats. Chemotherapy 32(S-3):316-326.
141. Nishimura, K., Nanto, T., Mukumoto, K., Yasuba, J., Sasaki, H., Terada, Y., Fukagawa, S., Shigematsu, K., and Tatsumi, H. 1976. Reproduction studies of pipemidic acid in rats. II. Teratogenicity study. lyakuhin Kenkyu 7(31):321-329.
142. Nomura, G., Watanabe, M., Kawakami, Y., Hirata, M., Suzuki, S., and Sunaga, M. 1988. Fifty-two- week oral chronic toxicity study of NY-198 in rats. Preclin. Rep. Cent. Inst. Exp. Anim. 14:1-21.
143. Norrby, S. R. 1991. Side-effects of quinolones: Comparisons between quinolones and other antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:378-383.
144. Nozaki, M., Tanaka, K., Takeda, N., Niwa, M., Kohno, Kobayashi, M., and Tsurumi, K. 1991. Neuro excitability of spafloxacin, a novel quinolone antibacterial drug, in combination with nonsteroidal anti-inflammatory drugs. Chemotherapy 39:167-174.
145. Obernauerova, M., Subik, J., and Ebringer, L. 1992. Ofloxacin induces cytoplasmic respiration-deficient mutants in yeast Saccharomyces cerevisiae. Curr. Cenet. 21:443-446.
146. Ohkubo, H., Segawa, M., Hirayama, T., and Nishino, K. 1981a. Pharmacological studies on AM-715: (I) Influences of AM-715 on central nervous system, peripheral nervous system and smooth muscle organs. Chemotherapy 29(S-4):965-984.
147. Ohkubo, H., Segawa, M., Hirayama, T., and Nishino, K. 1981b. Pharmacological studies on AM-715: (II) Influences of AM-715 on respiratory and cardiovascular system, exocrine and urinary system, and others. Chemotherapy 29(S-41):985-1001.
148. Oyama, S., Inasaka, H., Teramura, M., Sugiura, K., and Ueda, H. 1992. Two cases of photosensitive dermatitis induced by lomefloxacin. Hifu 34:457-461.
149. Paton, J. H., and Reeves, D. S. 1991. Clinical features and management of adverse effects of quinolone antibacterials. Drug Safety 6:8-27.
150. Peraino, C., Fry, R., Staffeldt, E., and Christopher, J. 1975. Comparative enhancing effect of phénobarbi-tal, diphenylhydantoin, and dichlorodiphenyl-trichloroethane on 2-acetyl-aminofluorene induced hepatic tumorigenesis in the rats. Cancer Res. 35:2884-2890.
151. Pertuiset, E., Lenoir, G., Jehanne, M., Douchain, F., Guillot, M., and Menkes, F. 1989. Tolerance articu-laire de la pefloxacine et de l’ofloxacine chez les enfants et adolescents atteints de muscoviscidose. Rev. Rhum. 56:735-740.
152. Phillips, G., Johnson, B. E., and Ferguson, J. 1990. The loss of antibiotic activity of ciprofloxacin by photodegradation. j. Antimicrob. Chemother. 26:783-789.
153. Phillips, I. 1987. Bacterial mutagenicity and the 4-quinolones. I. Antimicrob. Chemother. 20:771-773.
154. Phillips, I., Culebars, E., Moreno, F., and Baquero, F. 1987. Induction of the SOS response by new 4- quinolones. J. Antimicrob. Chemother. 20:631-638.
155. Physicians’ Desk Reference. 1993. Ciprofloxacin. 47th ed., pp. 1636-1639. Also Norfloxacin. 47th ed., pp. 1482-1483. Montvale, NJ: Medical Economics.
156. Piddock, L. J. V., and Wise, R. 1987. Induction of the SOS response in Escherichia coli by 4-quinolone antimicrobial agent. FEMS Microbiol. Lett. 41:289-294.
157. Pietras, R. J. 1981. Sex pheromone production by preputial gland: The regulatory role of estrogen. Chem. Senses. 6:391-408.
158. Pino, A., Maura, A., and Grillo, P. 1989. Absence of cinoxacin-induced DNA fragmentation and muta-tions in the rat granuloma pouch. Environ. Mol. Mutagen. 13:112-115.
159. Polonyi, J., Ebringer, L., Krajcovic, J., and Kapeller, K. 1990. Injured mitochondria in cells of Euglena gracilis after DNA gyrase inhibitors treatment. Z. Mikrosk.-Anat. Forsch. 104:61-78.
160. Power, E. G., and Phillips, I. 1993. Correlation between umuC induction and Salmonella mutagenicity assay for quinolone antimicrobial agents. FEMS Microbiol. Lett. 112:251-254.
161. Raeburn, J. A., Govan, J. R. W., McCrae, W. M., Greening, A. P., Collier, P. S., Hodson, M. E., and Goodchild, M. C. 1987. Ciprofloxacin therapy in cystic fibrosis. I. Antimicrob. Chemother. 20:295-296.
162. Ramsay, C. A., and Obreshfova, N. 1974. Photosensitivity from nalidixic acid. Br./. Dermatol. 91:523-528.
163. Rapp, L. M., Tolman, B. L., and Dhindsa, H. S. 1990. Separate mechanisms for retinal damage by ultra- violet-A and mid-visible light. Invest. Ophthalmol. Vis. Sci. 31:1186-1190.
164. Rumler, W., and Rohden, L. 1987. Does nalidixic acid produce joint toxicity in children? 15th Int. Congr. Chemotherapy, Proc. 1029-1031. Istanbul.
165. Sacks, L. E., and MacGregor, J. T. 1982. The B. subtilis multigene sporulation test for mutagens: Detection of mutagens inactive in the Salmonella his reversion test. Mutat. Res. 95:191-202.
166. Sato, H., Kajimura, T., and Takayama, S. 1994. Nalidixic acid on preputial and clitoral glands carcino-genesis initiated 3, 2’-dimethyl-4-aminobiphenyl. In Proceedings of the 10th Annual Meeting of the lapanese Society for Toxicology and Pathology, p. 60.
167. Sato, K., Hoshino, K., Une, T., and Osada, Y. 1989. Inhibitory effects of ofloxacin on DNA gyrase off. coli and topoisomerase II of bovine calf thymus. Rev. Infect. Dis. 11:915-916.
168. Sato, T., and Kobayashi, F. 1980. Teratological study on cinoxacin in rabbits. Chemotherapy 28(S-4):508-515.
169. Sato, T., Kaneko, Y., Saegusa, T., and Kobayashi, F. 1980. Reproduction studies of cinoxacin in rats. Chemotherapy 28(S-4):484-507.
170. Sawada, M., Nakamura, S., Yamada, A., Kobayashi, T., and Okada, S. 1991. Phase IV study and post-marketing surveillance of ofloxacin in Japan. Chemotherapy 37:134-142.
171. Schaad, U. B. 1991. Use of quinolones in pediatrics. Eur.J. Clin. Microbiol. Infect. Dis. 10:355-360.
172. Schaad, U. B., Stoupis, C., Wedgwood, J., Tschaeppeler, H., and Vock, P. 1991. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr. Infect. Dis. I. 10:723-729.
173. Schacht, P., Arden, G., Branolte, J., Bruck, H., Chysky, V., Griffith, E., Gruenwaldt, G., Hullmann, R., Konopka, C. A., O’Brien, B., Rahm, V., Ryoki, T., Westwood, A., and Weuta, H. 1988. Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection 16 (suppl. 1):S29-S43.
174. Schluter, G. 1986. Toxicology of ciprofloxacin. In Proceedings of the First International Workshop, eds. H. C. Neu and H. Weuta, pp. 61-67. Amsterdam: Excerpta Medica.
175. Schroter-Kermani, C., Hinz, N., Risse, P., Stahlmann, R., and Merker, H.-J. 1992. Effects of ofloxacin on chondrogenesis in murine cartilage organoid culture. Toxicol. In Vitro 6:465-474.
176. Script. 1993. FDA committee urges stronger warning on Searle’s Maxaquin, photocarcinogenicity. No. 1810/11, pp. 32-33.
177. Scully, B. E., Nakatomi, M., Ores, C., Davidson, S., and Neu, H. C. 1987. Ciprofloxacin therapy in cystic fibrosis. Am. J. Med. 82(suppl. 4A):196-201.
178. Senda, H., Satomura, K., Satoh, Y., Takemoto, Y., Ohnishi, K., Matsuoka, N., and Yoshida, K. 1984. Toxi-cological studies of AT-2266. Six-month chronic toxicity study in dogs. Chemotherapy 32:242-278.
179. Shah, P. M., and Mulert, R. 1990. Safety profile of quinolones. Eur. Urol. 17:46-51.
180. Shimada, H. 1993. Mutagenicity test battery for toxicity studies of drug: Status quo and prespective. Environ. Mutat. Res. Commun. 15:109-121.
181. Shimada, H., and Itoh, S. 1991. Effect of DU-6859 and the related quinolone antibacterial agents on mammalian chromosomes. 31st ICAAC abstr. 1507. Chicago.
182. Shimada, H., Morita, H., and Akimoto, T. 1980. Lack of induction of dominant lethal mutations in male mice by nalidixic acid. Toxicol. Lett. 7:165-170.
183. Shimada, H., Ebine, Y., Kurosawa, Y., and Arauchi, T. 1984. Mutagenicity studies of DL-8280, a new antibacterial drug. Chemotherapy 32(S-1):1162-1170.
184. Shimada, H., Ebine, Y., Sato, T., Kurosawa, Y., and Arauchi, T. 1985. Dominant lethal study in male mice treated with ofloxacin, a new antimicrobial drug. Mutat. Res. 144:51-55.
185. Shimada, H., Itoh, S., Hattori, C., Tada, S., and Matsuura, Y. 1992. Mutagenicity of the new quinolone antibacterial agent levofloxacin. Arzneim.-EorschJDrug Res. 43:378-385.
186. Shimoda, K., Yoshida, M., Wagai, N., Takayama, S., and Kato, M. 1993. Phototoxic lesions induced by quinolone antibacterial agents in auricular skin and retina of albino mice. Toxicol. Pathol. 21:554-561.
187. Shiratori, O., and Takase, S. 1980. Mutagenic activity test on cinoxacin in vitro and in vivo cytogenetic tests in mammalian cells. Chemotherapy 28(S-4):523-528.
188. Smythe, M. A., and Rybak, M. J. 1989. Ofloxacin: A review. Drug Intel/. Clin. Pharm./Ann. Pharmacother. 23:839-846.
189. Stahlmann, R., and Lode, H. 1988. Safety overview: Toxicity, adverse effects and drug interactions. In The quinolones, ed. V. Andriole, pp. 201-233. London: Academic Press.
190. Stahlmann, R., Merker, H. J., Hinz, N., Chahoud, I., Webb, J., Heger, W., and Neubert, D. 1990. Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Arch. Toxicol. 64:193-204.
191. Stahlmann, R., Forster, C., and Van Sickle, D. 1993. Quinolone in children. Are concerns over arthropa-thy justified? Drug Safety 9:397-403.
192. Stenchever, M. A., Powell, W., and Jarvis, J. A. 1970. Effect of nalidixic acid on human chromosome integrity. Am.J. Obstet. Gynecol. 107:329-330.
193. Suzuki, H., Takahashi, T., Sato, Y., and Abe, Y. 1990a. Fertility study of fleroxacin in rats. Chemotherapy 38(S-21):261-271.
194. Suzuki, H., Ishikawa, S., Ogawa, Y., Takahashi, T., and Abe, Y. 1990b. Teratological study of fleroxacin in rabbits. Chemotherapy 38(S-2):272-279.
195. Suzuki, T., Hara, Y., Tamagawa, M., Kakizawa, K., and Murayama, S. 1992. Effects of the combination of new quinolones and an anti-inflammatory drug, fenbufen, on the EEC of rabbits. Folia Pharmacol. Ipn. 99:45-54.
196. Taga, F., Kobayashi, F., Saito, S., Ooie, T., Kawahara, F., Uchida, H., Shimada, J., Hori, S., and Sakai, O. 1990. Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals. Arzneim.-Forsch./Drug Res. 40:900-904.
197. Takada, S., Kato, M., and Takayama, S. 1994. Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles. J. Toxicol. Environ. Health 42:73-88.
198. Takasuna, K. Kasai, Y., Usui, C., Takahashi, M., Hirohashi, M., Tamura, K., and Takayama, S. 1992. General pharmacology of the new quinolone antibacterial agent levofloxacin. Arzneim.- Forsch./Drug Res. 42:408-418.
199. Takayama, S., Watanabe, T., Akiyama, K., Ohura, K., Harada, S., Matsuhashi, K., Mochida, K., and Yamashita, N. 1986. Reproductive toxicity of ofloxacin. Arzneim.-Forsch./Drug Res. 36:1244-1248.
200. Takeda, N. 1990. Pharmacological study on CNS action of new quinolone with special reference to drug interaction with NSAID. Acta Sch. Med. Univ. Gifu 38:742-756.
201. Takemoto, Y., Senda, H., Nakano, S., Yamazoe, H., Yamayoshi, M., Matsuoka, N., Ohnishi, K., and Yoshida, K. 1984. Toxicological studies of AT-2266: Subacute and chronic toxicity studies in rats. Chemotherapy 32(S-3):199-220.
202. Tanaka, N., Yamakage, Y., Saitou, M., Hara, T., and Shibuya, T. 1988. Cytogenetic study of NY-198 on Chinese hamster cells. Chemotherapy 36(S-2):433-438.
203. Tatsumi, H., Senda, H., Yatera, S., Takemoto, Y., Yamayoshi, M., and Ohnishi, K. 1978. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J. Toxicol. Sci. 3:357-367.
204. Terada, Y., Nishimura, K., Komurasaki, M., Yoshioka, M., and Yoshida, K. 1984a. Reproduction studies of AT-2266. (1) Fertility study in rats. Chemotherapy 32(S-3):279-292.
205. Terada, Y., Nishimura, K., Takenaka, H., and Yoshida, K. 1984b. Reproduction studies of AT-2266. (2) Effects on male fertility in rats (serial mating study). Chemotherapy 32(S-3):293-300.
206. Terada, Y., Nishimura, K., Komurasaki, M., Tsuruta, K., Imura, Y., Yoshioka, M., and Yoshida, K. 1984c. Reproduction studies of AT-2266 (3) Teratogenicity study in rats. Chemotherapy 32(5-3): 301-315.
207. Terada, Y., Mukumoto, K., Imura, Y., Nishimura, K., and Ohnishi, K. 1991. Reproductive and develop-mental toxicity studies of sparfloxacin. (4) Teratogenicity study in rabbits. Yakuri to Chiryou 19:1289-1297.
208. Tokunaga, Y., Asaba, M., and Kato, R. 1979. Dominant lethal mutation test of miloxacin. Ohyo Yakuri. 18:37-45.
209. Tsuda, H., Hasegawa, R., Imaida, K., Masui, T., Malcolm, A., and Ito, N. 1984. Modifying potential of thirty-one chemicals on the short-term development of y-glutamyl transferase-positive in diethylni- trosamine-initiated rat liver. Gann 75:876-883.
210. Tsuji, A., Sato, H., Okezaki, E., Nagata, O., and Kato, H. 1988. Effect of the anti-inflammatory agent fenbufen on the quinolone-induced inhibition of y-aminobutyric acid binding to rat brain mem-brane in vitro. Biochem. Pharmacol. 37:4408-4411.
211. Ulitzur, S. 1982. A bioluminescence test for genotoxic agents. Trends Anal. Chem. 1:329-333.
212. Umemura, T., Sasa, H., lizuka, T., and Yanagita, T. 1988. Teratological study of oral administration of NY-198 in rabbits. Chemotherapy 36(S-2):391-410.
213. Vigier, P. R. R. 1974. Mutagenic effect of nalidixic acid on bacteriophage T4. Mutat. Res. 25:25-32.
214. Wagai, N., and Tawara, K. 1991a. Important role of oxygen metabolites in quinolone antibacterial agent- induced cutaneous phototoxicity in mice. Arch. Toxicol. 65:495-499.
215. Wagai, N. J and Tawara, K. 1991b. Quinolone antibacterial-agent-induced cutaneous phototoxicity: Ear swelling reactions in BALB/c mice. Toxicol. Lett. 58:215-223.
216. Wagai, N., and Tawara, K. 1992. Possible direct role of reactive oxygens in the cause of cutaneous pho-totoxicity induced by five quinolones in mice. Arch. Toxicol. 66:392-397.
217. Wagai, N., Yamaguchi, F., Tawara, K., and Onodera, T. 1989. Studies on experimental conditions for detecting phototoxic potentials in BALB/c mice. I. Toxicol. Sci. 14:197-204.
218. Wagai, N., Yamaguchi, F., Sekiguchi, M., and Tawara, K. 1990. Phototoxic potential of quinolone antibacterial agents in BALB/c mice. Toxicol. Lett. 54:299-308.
219. Wakisaki, H., Koike, S., and Makino, E. 1988. Mutagenicity studies on NY-198 in bacteria. Chemotherapy 36(S-2):422-427.
220. Watanabe, T., Fujikawa, K., Harada, S., Ohura, K., Sasaki, T., and Takayama, S. 1992. Reproductive toxicity of the new quinolone antibacterial agent levofloxacin in rats and rabbits. Arzneim.- ForschJDrug Res. 42:374-377.
221. Williams, P. D., and Helton, D. R. 1991. The proconvulsive activity of quinolone antibiotics in an animal model. Toxicol. Lett. 58:23-28.
222. Xu, J., Whong, W.-Z., and Ong, T.-M. 1984. Validation of the Salmonella (SV50)/arabinose-resistant forward mutation assay system with 26 compounds. Mutat. Res. 130:79-86.
223. Yamamoto, K., Yoshimura, K., and Matsushita, A. 1980. General pharmacology of cinoxacin. 1. Effects on the central nervous system. Chemotherapy 28(S-4):530-549.
224. Yamamoto, K., Naitoh, Y., Inoue, Y., and Yoshimura, K. 1988. Seizure discharges induced by the com-bination of a new quinolinecarboxylic acid antimicrobial drugs and non-steroidal anti-inflammatory drugs-Effect of NY-198 on the central nervous system. Chemotherapy 36(S-2):300-324.
225. Yasbin, R. E., and Miehl, R. 1980. Deoxyribonucleic acid repair in Bacillus subtilis: Development of competent cells into a tester for carcinogens. Appl. Environ. Microbiol. 39:854-858.
226. Yoshizawa, M., Hashimoto, A., and Asai, T. 1992. Photosensitive drug eruption due to lomefloxacin. Rinsho-Hifu 46:463-466.
227. Young, L. S. 1985. Clinical experience with the newer quinolones. Res. Clin. Forms 7:97-114.
228. Zbinden, G. 1988. Preface. In National and international drug safety guidelines, eds. S. Alder and G. Zbinden, pp. 5-6. Zollikon, Switzerland: M.T.C. Verlag Zollikon.
229. Zinner, S. H. 1989. Clinical overview of enoxacin. Clin. Pharmacokinet. 16(S-11):59-64.